Pembrolizumab for Advanced NSCLC and PS 2-3
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radiatio...
Age: 18 years - 66+
Gender: All
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in
patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to
other places in the body (metastatic), or cannot be removed by surgery (unresectable).
...
Age: 18 years - 66+
Gender: All
Pembrolizumab in MIBC
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing
two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis
with a standard acquisition protocol (as outlined in the protocol) as well as CT...
Age: 18 years - 66+
Gender: All
Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this research study is to determine the safety and tolerability of two dosing
schedules of cemiplimab given in combination with cisplatin and docetaxel induction
chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head ...
Age: 18 years - 66+
Gender: All
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug
conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once
every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovari...
Age: 18 years - 66+
Gender: Female
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 ...
Age: 18 years - 66+
Gender: All
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or
Metastatic Solid Tumors
Age: 18 years - 66+
Gender: All
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin
HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual
chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2
p...
Age: 18 years - 66+
Gender: Female
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drug...
Age: 18 years - 66+
Gender: All
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482)
plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the
adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.
...
Age: 18 years - 66+
Gender: All
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
This is a pilot, single-center, single-arm study where 20 patients with metastatic or
unresectable clear cell renal cell carcinoma will receive same sequential treatment strategy
(Cabozantinib for 12 weeks, then proceed with Ipilimumab plus Nivolumab immunotherapy x...
Age: 18 - 99 years
Gender: All
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
The purpose of this study is to assess the safety and efficacy of treatment with
pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with
mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not
...
Age: 18 years - 66+
Gender: Female
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in
participants with advanced (metastatic and/or unresectable) solid tumors.
Age: 18 years - 66+
Gender: All
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386
in combination with pembrolizumab in participants with previously treated selected solid
tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination ...
Age: 18 years - 66+
Gender: All
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination
with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide
versus standard therapy alone for the treatment of poorly differentiated extrapulmo...
Age: 18 years - 66+
Gender: All
Dupilumab_Metastatic NSCLC
This is an Phase Ib/2 study, single arm, single cohort study to determine the safety and
tolerability of Dupilumab with PD-(L)1 blockade for patients with relapsed/refractory
metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1...
Age: 18 years - 66+
Gender: All
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is a randomized, double-blind, multi-center phase III clinical study to compare
the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with
chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal c...
Age: 12 - 75 years
Gender: All
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
This phase II trial studies the side effects of chemotherapy and intensity modulated
radiation therapy in treating patients with low-risk HIV-associated anal cancer, and
nivolumab after standard of care chemotherapy and radiation therapy in treating patients with
...
Age: 18 years - 66+
Gender: All
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
This phase II/III trial compares the addition of radiation therapy to the usual treatment
(immunotherapy with or without chemotherapy [carboplatin, pemetrexed, paclitaxel,
nab-paclitaxel]) versus (vs.) usual treatment alone in treating patients with non-small cell
...
Age: 18 years - 66+
Gender: All